- Home
- ESPR vs NATH Comparison
ESPR vs NATH Comparison
Compare ESPR & NATH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- NATH
- Stock Information
- Founded
- ESPR 2008
- NATH 1916
- Country
- ESPR United States
- NATH United States
- Employees
- ESPR N/A
- NATH N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- NATH Restaurants
- Sector
- ESPR Health Care
- NATH Consumer Discretionary
- Exchange
- ESPR Nasdaq
- NATH Nasdaq
- Market Cap
- ESPR 534.3M
- NATH 442.2M
- IPO Year
- ESPR 2013
- NATH N/A
- Fundamental
- Price
- ESPR $2.97
- NATH $105.83
- Analyst Decision
- ESPR Buy
- NATH
- Analyst Count
- ESPR 6
- NATH 0
- Target Price
- ESPR $6.50
- NATH N/A
- AVG Volume (30 Days)
- ESPR 7.1M
- NATH 37.6K
- Earning Date
- ESPR 11-06-2025
- NATH 11-07-2025
- Dividend Yield
- ESPR N/A
- NATH 1.89%
- EPS Growth
- ESPR N/A
- NATH 9.62
- EPS
- ESPR N/A
- NATH 5.77
- Revenue
- ESPR $268,125,000.00
- NATH $150,413,000.00
- Revenue This Year
- ESPR $18.83
- NATH N/A
- Revenue Next Year
- ESPR N/A
- NATH N/A
- P/E Ratio
- ESPR N/A
- NATH $18.35
- Revenue Growth
- ESPR N/A
- NATH 6.38
- 52 Week Low
- ESPR $0.69
- NATH $75.15
- 52 Week High
- ESPR $3.94
- NATH $118.50
- Technical
- Relative Strength Index (RSI)
- ESPR 59.21
- NATH 44.90
- Support Level
- ESPR $2.80
- NATH $104.02
- Resistance Level
- ESPR $3.11
- NATH $109.98
- Average True Range (ATR)
- ESPR 0.17
- NATH 2.09
- MACD
- ESPR 0.01
- NATH -0.50
- Stochastic Oscillator
- ESPR 76.47
- NATH 24.74
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About NATH Nathan's Famous Inc.
Nathan's Famous Inc is an owner of fast food franchises in the United States. The company's reportable segment includes the Branded Product Program, Product licensing, Restaurant operations and Corporate. Branded Product Program derives revenue principally from the sale of hot dog products either directly to foodservice operators or to various foodservice distributors who resell the products to foodservice operators. It generates maximum revenue from the Branded Product Program segment. Geographically, it derives a majority of revenue from the United States.